<!DOCTYPE html>

<html lang="en" data-theme="light">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Estrogens, Progestins & Contraceptives - Essentials of Medical Pharmacology</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link
        href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap"
        rel="stylesheet">

    <link rel="stylesheet" href="../styles/main.css">

    <script>
        MathJax = {
            tex: {
                inlineMath: [['$', '$'], ['\\(', '\\)']],
                displayMath: [['$$', '$$'], ['\\[', '\\]']],
                processEscapes: true,
                processEnvironments: true
            },
            svg: { fontCache: 'global' },
            options: {
                skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
            }
        };
    </script>

    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>

</head>

<body>
    <a href="#main-content" class="skip-link">Skip to main content</a>

    <button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
        <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
        <span class="theme-toggle-icon dark-icon">üåô</span>
    </button>

    <div class="reading-progress-container">
        <div class="reading-progress-bar" id="reading-progress"></div>
    </div>

    <!-- Floating TOC -->

    <nav class="floating-toc" id="floating-toc">
        <div class="floating-toc-header">
            <span>üìë</span> Table of Contents
        </div>
        <ul class="floating-toc-list">
            <li><a href="#estrogens">Estrogens</a></li>
            <li><a href="#hrt">Hormone Replacement Therapy</a></li>
            <li><a href="#serms-ais">SERMs & Aromatase Inhibitors</a></li>
            <li><a href="#progestins">Progestins</a></li>
            <li><a href="#antiprogestins">Antiprogestins (Mifepristone)</a></li>
            <li><a href="#contraceptives">Hormonal Contraceptives</a></li>
            <li><a href="#emergency-contraception">Emergency Contraception</a></li>
            <li><a href="#case-study">Problem Directed Study</a></li>
        </ul>
    </nav>

    <div class="page-wrapper">
        <div class="container">
            <article class="document-article">
                <header class="document-header">
                    <div class="header-badge">
                        <span>‚ôÄÔ∏è</span>
                        <span>Topic 23</span>
                    </div>
                    <h1 class="document-title">Estrogens, Progestins and Contraceptives</h1>
                    <div class="title-meta">
                        <div class="meta-item">
                            <span>üìö</span>
                            <span>Hormones and Related Drugs</span>
                        </div>
                        <div class="meta-item">
                            <span>‚è±Ô∏è</span>
                            <span>60 min read</span>
                        </div>
                    </div>
                </header>

                <main id="main-content" class="content-wrapper">
                    <!-- Section 1: Estrogens -->
                    <section class="content-section" id="estrogens">
                        <div class="section-header">
                            <div class="section-number">01</div>
                            <h2 class="section-title">
                                <span class="title-icon">üß¨</span>
                                Estrogens
                            </h2>
                        </div>

                        <div class="content-card">
                            <p><strong>Estradiol</strong> is the major natural estrogen. It is rapidly metabolized in
                                the liver, making it inactive orally.</p>

                            <h3>Synthetic Estrogens</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><strong>Steroidal:</strong> Ethinylestradiol, Mestranol, Tibolone.
                                </li>
                                <li class="list-item"><strong>Nonsteroidal:</strong> Diethylstilbestrol (DES) - rarely
                                    used now.</li>
                            </ul>

                            <h3>Actions</h3>
                            <ul>
                                <li><strong>Reproductive:</strong> Growth of uterus/vagina, proliferation of
                                    endometrium, induction of watery cervical secretion, ductal growth in breast.</li>
                                <li><strong>Metabolic:</strong> Anabolic (weaker than testosterone), fusion of
                                    epiphyses.</li>
                                <li><strong>Bone:</strong> Retards bone resorption (maintains bone mass).</li>
                                <li><strong>Lipid Profile:</strong> Beneficial. Increases HDL, decreases LDL.</li>
                                <li><strong>Coagulation:</strong> Increases clotting factors (prothrombotic).</li>
                            </ul>

                            <div class="callout callout--info">
                                <div class="callout-header">
                                    <span class="callout-icon">‚ÑπÔ∏è</span>
                                    <h4 class="callout-title">Mechanism</h4>
                                </div>
                                <div class="callout-content">
                                    <p>Bind to nuclear <strong>Estrogen Receptors (ER$\alpha$ and ER$\beta$)</strong>
                                        $\rightarrow$ Dimerization $\rightarrow$ Binding to Estrogen Response Elements
                                        (ERE) on DNA $\rightarrow$ Gene transcription.</p>
                                </div>
                            </div>
                        </div>
                    </section>

                    <!-- Section 2: HRT -->
                    <section class="content-section" id="hrt">
                        <div class="section-header">
                            <div class="section-number">02</div>
                            <h2 class="section-title">
                                <span class="title-icon">üëµ</span>
                                Hormone Replacement Therapy (HRT)
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Used for menopausal symptoms (hot flashes, urogenital atrophy, osteoporosis risk).
                                Generally restricted to women < 60 years or within 10 years of menopause.</p>

                                    <h3>Current Guidelines</h3>
                                    <ul class="enhanced-list">
                                        <li class="list-item"><strong>Vasomotor Symptoms:</strong> Primary indication.
                                            Use smallest effective dose for shortest duration.</li>
                                        <li class="list-item"><strong>Intact Uterus:</strong> Must use <strong>Estrogen
                                                + Progestin</strong> (to prevent endometrial cancer).</li>
                                        <li class="list-item"><strong>Hysterectomized:</strong> Use <strong>Estrogen
                                                alone</strong>.</li>
                                        <li class="list-item"><strong>Osteoporosis:</strong> Not first line
                                            (Bisphosphonates are preferred). Used if other drugs are not tolerated.</li>
                                    </ul>

                                    <div class="callout callout--warning">
                                        <div class="callout-header">
                                            <span class="callout-icon">‚ö†Ô∏è</span>
                                            <h4 class="callout-title">Risks of Combined HRT (WHI Study)</h4>
                                        </div>
                                        <div class="callout-content">
                                            <ul>
                                                <li>Increased risk of <strong>Breast Cancer</strong>.</li>
                                                <li>Increased risk of <strong>Venous Thromboembolism</strong> (DVT/PE).
                                                </li>
                                                <li>Increased risk of <strong>Stroke</strong> and Coronary Artery
                                                    Disease (in older women).</li>
                                                <li>Increased risk of <strong>Dementia</strong>.</li>
                                            </ul>
                                        </div>
                                    </div>

                                    <p><strong>Tibolone:</strong> A tissue-specific steroid (STEAR) that has estrogenic,
                                        progestational, and weak androgenic actions. Relieves symptoms and prevents
                                        osteoporosis without stimulating endometrium.</p>
                        </div>
                    </section>

                    <!-- Section 3: SERMs & AIs -->
                    <section class="content-section" id="serms-ais">
                        <div class="section-header">
                            <div class="section-number">03</div>
                            <h2 class="section-title">
                                <span class="title-icon">üé≠</span>
                                Antiestrogens, SERMs & Aromatase Inhibitors
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>1. Clomiphene Citrate</h3>
                            <p><strong>Mechanism:</strong> Blocks estrogen negative feedback on pituitary $\rightarrow$
                                Increased FSH/LH secretion $\rightarrow$ Induction of Ovulation.</p>
                            <p><strong>Use:</strong> Drug of choice for infertility due to anovulatory cycles.</p>

                            <h3>2. Selective Estrogen Receptor Modulators (SERMs)</h3>
                            <p>Tissue-selective actions (Agonist in some, Antagonist in others).</p>

                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Drug</th>
                                            <th>Breast</th>
                                            <th>Endometrium</th>
                                            <th>Bone</th>
                                            <th>Use</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>Tamoxifen</strong></td>
                                            <td>Antagonist</td>
                                            <td>Agonist (Hyperplasia risk)</td>
                                            <td>Agonist</td>
                                            <td>Breast Cancer (ER+ive)</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Raloxifene</strong></td>
                                            <td>Antagonist</td>
                                            <td>Antagonist (Safe)</td>
                                            <td>Agonist</td>
                                            <td>Osteoporosis (Postmenopausal)</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Toremifene</strong></td>
                                            <td>Antagonist</td>
                                            <td>Agonist</td>
                                            <td>Agonist</td>
                                            <td>Breast Cancer</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>

                            <h3>3. Aromatase Inhibitors (AIs)</h3>
                            <p><strong>Letrozole, Anastrozole, Exemestane.</strong></p>
                            <p>Inhibit the enzyme aromatase (which converts androgens to estrogens). More effective than
                                Tamoxifen for breast cancer in <strong>postmenopausal</strong> women (ovaries not
                                functional; estrogen comes from peripheral aromatization). <strong>Not
                                    effective</strong> in premenopausal women unless ovarian suppression is done.</p>

                            <h3>4. SERD</h3>
                            <p><strong>Fulvestrant:</strong> Selective Estrogen Receptor Down-regulator. Pure
                                antagonist. Used in Tamoxifen-resistant breast cancer.</p>
                        </div>
                    </section>

                    <!-- Section 4: Progestins -->
                    <section class="content-section" id="progestins">
                        <div class="section-header">
                            <div class="section-number">04</div>
                            <h2 class="section-title">
                                <span class="title-icon">üß¨</span>
                                Progestins
                            </h2>
                        </div>

                        <div class="content-card">
                            <p><strong>Natural:</strong> Progesterone (short acting, inactive orally). Micronized
                                progesterone is orally active.</p>
                            <p><strong>Synthetic:</strong></p>
                            <ul>
                                <li><strong>Progesterone derivatives:</strong> Medroxyprogesterone acetate (MPA),
                                    Megestrol, Dydrogesterone.</li>
                                <li><strong>19-Nortestosterone derivatives (Estranes):</strong> Norethindrone
                                    (Norethisterone).</li>
                                <li><strong>Gonanes (Potent):</strong> Levonorgestrel, Desogestrel, Norgestimate.</li>
                            </ul>

                            <h3>Uses</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><strong>Contraception:</strong> (Most common use).</li>
                                <li class="list-item"><strong>HRT:</strong> To protect endometrium.</li>
                                <li class="list-item"><strong>Dysfunctional Uterine Bleeding (DUB):</strong>
                                    Norethindrone.</li>
                                <li class="list-item"><strong>Endometriosis:</strong> Induces atrophy of ectopic
                                    endometrium.</li>
                                <li class="list-item"><strong>Threatened Abortion:</strong> (Efficacy controversial).
                                </li>
                            </ul>
                        </div>
                    </section>

                    <!-- Section 5: Antiprogestins -->
                    <section class="content-section" id="antiprogestins">
                        <div class="section-header">
                            <div class="section-number">05</div>
                            <h2 class="section-title">
                                <span class="title-icon">üõë</span>
                                Antiprogestins
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>Mifepristone (RU-486)</h3>
                            <p>A progesterone receptor antagonist (partial agonist in absence of progesterone). Also has
                                antiglucocorticoid activity.</p>
                            <p><strong>Actions:</strong> Sensitizes myometrium to prostaglandins, causes decidual
                                necrosis and detachment of blastocyst, softens cervix.</p>
                            <p><strong>Uses:</strong></p>
                            <ul>
                                <li><strong>Medical Termination of Pregnancy (MTP):</strong> Up to 7 weeks (now extended
                                    to 9 weeks/63 days).<br>
                                    <strong>Regimen:</strong> Mifepristone 200 mg (Oral) $\rightarrow$ 48 hrs later
                                    $\rightarrow$ Misoprostol 400-800 $\mu$g (Oral/Vaginal). Success rate > 90%.
                                </li>
                                <li><strong>Emergency Contraception.</strong></li>
                                <li><strong>Cervical Ripening.</strong></li>
                                <li><strong>Cushing's Syndrome</strong> (due to antiglucocorticoid action).</li>
                            </ul>
                        </div>
                    </section>

                    <!-- Section 6: Contraceptives -->
                    <section class="content-section" id="contraceptives">
                        <div class="section-header">
                            <div class="section-number">06</div>
                            <h2 class="section-title">
                                <span class="title-icon">üíä</span>
                                Hormonal Contraceptives
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>1. Combined Oral Pills (COC)</h3>
                            <p>Estrogen (Ethinylestradiol 30 $\mu$g) + Progestin (Levonorgestrel/Desogestrel). Taken for
                                21 days + 7 days gap/iron pills.</p>
                            <p><strong>Mechanism:</strong>
                            <ol>
                                <li><strong>Inhibition of Ovulation:</strong> Suppression of FSH/LH surge (Primary
                                    mechanism).</li>
                                <li><strong>Cervical Mucus:</strong> Makes it thick and hostile to sperm.</li>
                                <li><strong>Endometrium:</strong> Makes it unsuitable for implantation.</li>
                            </ol>
                            </p>

                            <h3>2. Progestin-Only Pill (Minipill)</h3>
                            <p>Taken continuously. No estrogen. Suitable for lactating women. Mechanism: Mainly cervical
                                mucus thickening and endometrial atrophy. Ovulation inhibited in only ~50%.</p>

                            <h3>3. Injectables</h3>
                            <p><strong>DMPA (Depot Medroxyprogesterone Acetate):</strong> 150 mg i.m. every 3 months.
                                Highly effective. Causes amenorrhoea and delayed return of fertility.</p>

                            <div class="callout callout--danger">
                                <div class="callout-header">
                                    <span class="callout-icon">‚ö†Ô∏è</span>
                                    <h4 class="callout-title">Adverse Effects & Contraindications of COCs</h4>
                                </div>
                                <div class="callout-content">
                                    <p><strong>Serious Risks:</strong> Venous Thromboembolism (DVT/PE), MI/Stroke (in
                                        smokers > 35 yrs), Hypertension.</p>
                                    <p><strong>Contraindications:</strong> H/o Thromboembolism/Stroke/CAD, Active Liver
                                        Disease, Breast/Genital Cancer, Undiagnosed vaginal bleeding, Pregnancy, Heavy
                                        smokers > 35 yrs.</p>
                                </div>
                            </div>

                            <div class="callout callout--success">
                                <div class="callout-header">
                                    <span class="callout-icon">‚úÖ</span>
                                    <h4 class="callout-title">Non-Contraceptive Benefits</h4>
                                </div>
                                <div class="callout-content">
                                    <p>Reduced risk of Ovarian and Endometrial cancer. Reduced menstrual blood loss
                                        (anemia), dysmenorrhoea, benign breast disease.</p>
                                </div>
                            </div>
                        </div>
                    </section>

                    <!-- Section 7: Emergency Contraception -->
                    <section class="content-section" id="emergency-contraception">
                        <div class="section-header">
                            <div class="section-number">07</div>
                            <h2 class="section-title">
                                <span class="title-icon">üöë</span>
                                Emergency Contraception (Postcoital)
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>To prevent pregnancy after unprotected intercourse.</p>
                            <ol class="enhanced-list">
                                <li class="list-item"><strong>Levonorgestrel (1.5 mg):</strong> Single dose within 72
                                    hours. Standard method (i-Pill). High efficacy, less nausea.</li>
                                <li class="list-item"><strong>Ulipristal (30 mg):</strong> Selective Progesterone
                                    Receptor Modulator. Effective up to 120 hours (5 days). More effective than
                                    Levonorgestrel.</li>
                                <li class="list-item"><strong>Mifepristone (600 mg):</strong> Highly effective.</li>
                                <li class="list-item"><strong>Copper-T Insertion:</strong> Within 5 days. Most
                                    effective.</li>
                            </ol>
                        </div>
                    </section>

                    <!-- Section 8: Case Study -->
                    <section class="content-section" id="case-study">
                        <div class="section-header">
                            <div class="section-number">08</div>
                            <h2 class="section-title">
                                <span class="title-icon">ü§î</span>
                                Problem Directed Study
                            </h2>
                        </div>

                        <div class="content-card">
                            <div class="callout callout--note">
                                <div class="callout-header">
                                    <span class="callout-icon">üìù</span>
                                    <h4 class="callout-title">Case 22.1</h4>
                                </div>
                                <div class="callout-content">
                                    <p>A 55-year-old postmenopausal woman on Tamoxifen adjuvant therapy for breast
                                        cancer (ER+ive) for 1 year is found to have thickening of endometrium on
                                        ultrasound.</p>
                                    <p><strong>(a) Cause:</strong> Tamoxifen acts as an <strong>estrogen
                                            agonist</strong> on the endometrium (while being antagonist in breast). This
                                        causes endometrial proliferation/hyperplasia, increasing the risk of endometrial
                                        carcinoma.</p>
                                    <p><strong>(b) Recommendation:</strong> Since she is postmenopausal, the therapy
                                        should ideally be <strong>switched to an Aromatase Inhibitor</strong> (Letrozole
                                        or Anastrozole). AIs are more effective in postmenopausal women and do not cause
                                        endometrial hyperplasia (though they increase osteoporosis risk).</p>
                                </div>
                            </div>

                            <div class="callout callout--note">
                                <div class="callout-header">
                                    <span class="callout-icon">üìù</span>
                                    <h4 class="callout-title">Case 22.2</h4>
                                </div>
                                <div class="callout-content">
                                    <p>28-year-old mother (9 month baby) wants oral contraceptives.</p>
                                    <p><strong>Advice:</strong> History: Check for contraindications (Thromboembolism,
                                        Liver disease, Breast cancer, Smoking, Migraine). Exam: BP, Breast exam, Pelvic
                                        exam. Investigations: Urine sugar/protein. If normal, a low-dose Combined Oral
                                        Pill is suitable. Since baby is 9 months old, lactation is less likely to be
                                        affected significantly, though progestin-only pill is safer for lactation.
                                        However, combined pills are more reliable for cycle control.</p>
                                </div>
                            </div>
                        </div>
                    </section>

                </main>

                <nav class="document-nav">
                    <div class="nav-container">
                        <a href="topic-22-androgens.html" class="nav-button nav-button--large nav-button--previous">
                            <div class="nav-label">Previous</div>
                            <div class="nav-title">Androgens & ED Drugs</div>
                        </a>

                        <div class="document-progress">
                            <div class="progress-indicator">
                                <span>23</span>
                                <span class="progress-separator">/</span>
                                <span>27</span>
                            </div>
                            <div class="progress-bar-container">
                                <div class="progress-bar-fill" style="width: 85%;"></div>
                            </div>
                            <div class="progress-label">Topic Progress</div>
                        </div>

                        <a href="topic-24-uterine.html" class="nav-button nav-button--large nav-button--next">
                            <div class="nav-label">Next</div>
                            <div class="nav-title">Oxytocin & Uterine Drugs</div>
                        </a>
                    </div>
                </nav>
            </article>
        </div>
    </div>

    <script src="../js/theme.js"></script>

    <script src="../js/navigation.js"></script>

    <script src="../js/interactions.js"></script>

</body>

</html>